NEWS & PUBLICATIONS
Welcome to the lab.
Discover more about our latest news, events and breakthroughs that have laid the groundwork for ExcellGene’s scientific foundation. Explore a variety of publications authored or co-authored by Florian and Maria Wurm, alongside ExcellGene scientists, spanning over three decades.
Blog Posts
One molecule against multiple COVID virus variants – philantropic $3.6 Billion CEPI organisation & ExcellGene collaborating for global defense
A delegation of CEPI (Coalition of Epidemic Preparedness and Innovation) was received by ExcellGene SA, the biotech service company in Monthey, on December 4th for a two day scientific discussion event. The meeting was held together with delegations from India (Bharat Biotech, Hyderabad, India) and Australia (University of Sydney, Prof. Jamie Triccas) which, together with ExcellGene, constitutes a three – party consortium funded by CEPI with a grant of 19 million US dollars.
On-demand webinar
Join ExcellGene SA, a company providing AAV production processes and develops such processes for its clients, in a free webinar. Dr. Yoann Saucereau, a research associate at ExcellGene, will discuss a fast and dependable method to assess the quantity and quality of particles during various stages of Adeno-Associated Virus (AAV) production.
Excellgene SA Symposium on Modern Vaccines
Our world needs innovation in vaccine manufacturing
Making vaccines and therapeutic products for the world is a highly complex enterprise. The COVID-19 pandemic has shown a great need for science and technology to quickly develop effective and affordable solutions.
From DNA to Therapeutic Protein in CHO Cells
The repeated Ebola virus outbreaks in West Africa have reached historic proportions and underscore the vulnerability of populations to pathogens. ExcellGene and 12 others are working together to create an effective preventive vaccine.
Free Virtual Talk and Q&A: From DNA to Therapeutic Protein in CHO Cells
The repeated Ebola virus outbreaks in West Africa have reached historic proportions and underscore the vulnerability of populations to pathogens. ExcellGene and 12 others are working together to create an effective preventive vaccine.
Single Use Bioreactors & Disposable Process Materials, How-To & Issues
Disposable materials in bioprocessing and single-use bioreactors have become widely used standards in R&D at small scale as well as cGMP based manufacturing. Both founders of ExcellGene SA (Dr. Maria J. Wurm, CEO, and Dr. Florian M. Wurm, CSO) gave talks about single-use bioreactors at the Disposable Solutions Forum in Berlin, February 19, 2020.
Smart Strategies to Enhance Productivity, Improve Titers, Cell Culture Performance and Product Quality @ BioProduction 2019
ExcellGene attended BioProduction 2019 in Frankfurt, November 5-7th 2019. Prof. Florian Wurm spoke under the cell line development track to cover strategies for improving yield and quality of recombinant proteins in CHO cells.
Future of Transient Gene Expression Keynote @ PEGS Europe 2018
Prof. Dr. F. Wurm was the keynote speaker in the Optimizing Expression Platforms conference at PEGS Summit Europe in Lisbon, Portugal in November 2018.
Transient Gene Expression: Paper Submissions Welcome
Transient Gene Expression for Rapid Protein Supply is the topic of an upcoming Special Issue in Processes, an open access journal of chemical and biological process engineering.
Better media and feeds for higher CHO yield
Better media and feeds for higher CHO yield In an article written in November 2017 by Dr. Angelo...
Press Releases
ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture
OKLAHOMA CITY, Oklahoma, MONTHEY, Switzerland, May 8, 2024 – ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
ExcellGene and Capricorn Scientific Forge Strategic Partnership to Revolutionize Biopharmaceutical Production
Monthey, Switzerland, 27/02/2024 – ExcellGene, a renowned Swiss biologics CDMO specializing in...
EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.
LOTTE BIOLOGICS and EXCELLGENE today announced the signing of a Memorandum of Understanding to collaborate in the biopharmaceutical Contract Development Organization (CDO) business. With this agreement, LOTTE BIOLOGICS will be able to proactively promote its CDO business by attracting a large number of customers ahead of its long-term strategy of expanding its Syracuse plant and constructing a factory in Korea.
Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
The astonishing speed with which coronavirus disease 2019 (COVID- 19) vaccines were developed is nothing short of a scientific triumph. Their rapid development was in part enabled by the use of novel gene-delivery technologies that could be manufactured quickly and at scale1.
Innovation in Vaccine Manufacturing
The COVID-19 pandemic has emphasized the urgent need for science and technology to develop effective and affordable solutions to make vaccines accessible quickly and on a global level. Poor manufacturability remains however one of the major bottlenecks that often prevents great science from reaching public health objectives.
Developing a Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene Partnership with Bharat Biotech and the University of Sydney.
Developing a Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene Partnership with Bharat...
Dr. Kiseljak, ExcellGene COO To Drive Recombinant Protein Expression
ExcellGene SA, a private-company offering services of research, development, and manufacturing for the biopharmaceutical industry for 20 years, announced today the promotion of Dr. Divor Kiseljak to Chief Operations Officer (COO).
CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development
Prices of recombinant proteins for therapy and industrial (non-medical) uses differ 100 to 10,000 fold. Why?
Manufacturing SARS-CoV-2 Omicron spike protein in grams
Prices of recombinant proteins for therapy and industrial (non-medical) uses differ 100 to 10,000 fold. Why?
Twenty Years
Prices of recombinant proteins for therapy and industrial (non-medical) uses differ 100 to 10,000 fold. Why?
Scientific Publications
A superior HEK cell line for AAV production
A superior HEK cell line for AAV productionWriter's Insight Derived from ExcellGene's HEKExpress® cells, a widely used cell system known for its transient and stable protein expression, a new host system with superior performance has been developed. This innovative...
Naming CHO Cells for Bio-manufacturing
Introduction Over the last 3 decades, CHO cells have become the most popular cell line for production of recombinant proteins for human therapy. In fact, nine of the world's 15 top selling drugs are protein therapeutics derived from CHO cells—with 76 Billion US...
Subunit Vaccine Production in CHO cells: Development of an Efficacious Ebola Virus Vaccine
Subunit Vaccine Production in CHO cells: Development of an Efficacious Ebola Virus Vaccine Candidate Authors Florian M. Wurm PhD, Prof. Emeri. Chief Scientific Officer, Founder Divor Kiseljak PhD Director of Process Science 20th April 2020 | Last updated: 3rd August...
Proteins for Industrial vs. Pharmaceutical Use: Review of Process and Pricing
Introduction Humans have been using cultured cells since the dawn of civilization [1,2]. A case can be made that the fermentation of grains by microbes into beer lead to the rise of agriculture and city-states [2]. For centuries, microbes were primarily used to...
Whitepapers
Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens (Summary)
In the early months of 2020, it became clear that the world was facing a new threat: a contagious, potentially lethal corona virus originated in Wuhan, China. This virus was named SARS-CoV-2 and it brought a new disease upon the world: COVID-19.
New White Paper: CHO Quasispecies – Implications for Manufacturing Processes
The White Paper CHO Quasispecies – Implications for Manufacturing Processes is now freely available for viewing on our website. First published in Processes Journal in 2013, it has since been viewed over 12,000 times and has been cited more than a hundred times.
CHO Quasispecies – Implications for Manufacturing Processes
Introduction Chinese hamster ovary (CHO) cells are, today, the gold standard for the manufacturing of therapeutic proteins. The overall value of products derived from these cells exceeds 50 billion US $ annually, and significant research and development efforts are...
Cloning of CHO Cells, Productivity and Genetic Stability – a Discussion
Mammalian cell culture-based manufacturing for biopharmaceuticals is perceived as an established technology. Many open questions remain.
New White Paper: Cloning of CHO Cells, Productivity and Genetic Stability, Best Paper Award, Keynote Lecture on CHO
New White Paper: Cloning of CHO Cells, Productivity and Genetic Stability, Best Paper Award, Keynote Lecture on CHO